Zim Laboratories Limited — Board Meeting, 20-05-2025: Outcome of Board Meeting

ZIM Laboratories has announced a board meeting on 20 May 2025 approving the financial results for the quarter and half-year. The company posted consolidated revenues of ₹379.03 Cr for FY25 with net profit at ₹12.17 Cr, down from ₹17.25 Cr last year as operating expenses climbed due to higher employee costs and finance charges. No dividend was declared. Capex stood at ₹40.79 Cr, focusing on pharma manufacturing and R&D expansion. The balance sheet remains strong with equity at ₹252.24 Cr and manageable debt. The audit was clean, reflecting transparent financials.